Century Therapeutics, Inc. IPSC

1.67 (0.02) (1.18%) as of 25 Sep
Market cap
$306.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 — — — —
P/S ratio
0.75 12.06 96.60 55.21 — — — —
P/FCF ratio
0.00 0.00 0.00 0.00 — — — —
P/Operating CF
(5.38) (3.28) (8.23) (12.53) — — — —
P/B ratio
0.54 0.49 1.17 0.95 — — — —
Price to Tangible BV
0.69 0.62 1.17 0.95 — — — —
EV/Sales
(0.27) (16.66) 19.60 (3.20) — — — —
EV/EBITDA
4.68 0.85 0.00 0.13 — — — —
EV/Operating CF
0.29 1.00 (0.50) (1.18) — — — —
EV/FCF
0.29 1.00 (0.43) 1.00 — — — —
Quick Ratio
5.79 1.46 9.68 10.58 14.24 6.25 27.28 —
Current Ratio
5.97 1.50 9.92 10.72 14.57 6.51 28.10 —
Net Debt/EBITDA
17.95 1.46 1.25 2.43 2.31 1.26 4.12 —
Debt/Assets
0.01% 0.02% 0.18% 2.43% 2.96% 9.25% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.04 0.03 0.13 0.00 —
Asset Turnover
0.38 0.02 0.01 0.01 0.00 0.00 0.00 —
Operating CF/Net income
10.84 0.87 0.65 (0.11) 0.93 0.77 0.07 —
Capex/Depreciation
(0.08) (0.02) (1.50) (3.50) (11.09) (6.58) 0.00 —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(5.98%) (73.14%) (56.07%) (37.46%) (66.13%) 83.53% (186.03%) —
ROA
(3.32%) (35.46%) (32.26%) (28.34%) (35.22%) (40.03%) (304.26%) —
ROIC
(25.79%) 0.00% (723.93%) 0.00% (31.83%) (450.83%) 0.00% —
Return on Tangible Assets
(6.36%) (100.12%) (59.20%) (35.13%) (35.43%) (65.28%) (292.73%) —
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Research and Development Expense of Revenue
87.64% 1,627.62% 4,371.81% 2,061.42% 0.00% 0.00% 0.00% —
Selling, General and Administrative Expense of Revenue
21.99% 503.19% 1,552.84% 612.75% 0.00% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.15 0.10 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
6.27% 192.56% 654.23% 205.21% 0.00% 0.00% — —
Graham Net Nets
0.65 0.03 0.00 0.47 — — — —
Graham Number
0.00 0.00 0.00 0.00 — — — —
Earnings Yield
(14.00%) (161.39%) (62.91%) (45.88%) — — — —
Free Cash Flow Yield
(120.99%) (138.84%) (47.28%) (5.77%) — — — —
Revenue per Share
1.26 0.08 0.04 0.09 0.00 0.00 0.00 —
Operating CF per Share
(1.20) (1.40) (1.49) 0.24 (2.75) (5.52) (0.29) —
Capex per Share
(0.01) 0.00 (0.23) (0.53) (1.39) (1.31) 0.00 —
Free Cash Flow per Share
(1.21) (1.40) (1.72) (0.29) (4.14) (6.83) (0.29) —
Cash per Share
1.35 2.41 2.91 5.46 6.88 10.12 1.49 —
Shareholders Equity per Share
1.84 2.05 3.11 5.24 12.23 9.80 2.88 —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
1.84 2.05 3.11 5.24 12.23 9.80 2.88 —
Free Cash Flow
(104.72) (110.29) (102.08) (16.55) (133.97) (51.09) (16.17) —
Working Capital
100.54 64.27 159.15 289.90 212.50 66.69 81.13 —
Capital Expenditures
(0.85) (0.15) (13.74) (30.60) (44.97) (9.82) (2.46) —
Net Current Asset Value
56.00 2.20 1.05 135.92 187.02 45.37 81.13 —
EV/EBIT
1.77 0.79 0.00 0.12 — — — —
Capex to Sales
0.01 0.02 6.15 5.89 0.00 0.00 — —
Net Profit Margin
(8.78%) (1,920.87%) (6,115.12%) (2,518.41%) 0.00% 0.00% 0.00% —
Price to Operating Income
0.00 0.00 0.00 0.00 — — — —
Other line items
Depreciation/Fixed assets
0.21 0.14 0.13 0.11 0.07 0.10 0.10 —
Cash ROIC
(55.75%) (49.12%) (44.69%) (10.91%) (23.25%) (35.64%) (7.79%) —
Accounts Receivable Turnover
0.00 0.00 0.00 10.10 0.00 0.00 0.00 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.05 —
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 2,269.16 —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 —
Average Receivables
— — — 0.52 0.58 0.52 0.52 —
Average Payables
3.92 2.91 4.10 6.53 7.84 4.82 4.82 —
Average Assets
288.46 356.95 423.62 461.96 272.08 133.84 80.45 —
Average Common Equity
160.15 173.06 243.74 349.49 144.91 (64.14) 131.58 —

Fold the line items

Columns are period end dates